Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Rating Upgraded by StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Brainstorm Cell Therapeutics Stock Down 1.6 %

Shares of BCLI opened at $1.24 on Wednesday. The stock’s 50-day moving average price is $2.30 and its 200 day moving average price is $4.57. The firm has a market capitalization of $7.07 million, a price-to-earnings ratio of -0.26 and a beta of 0.40. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.